The King Hussein Cancer Center (KHCC), the largest specialised cancer institution in the Middle East, plays a strategic role in the MILenARI consortium. With a highly active Bone Marrow Transplant Programme and newly built cell therapy facilities, KHCC is poised to become a regional hub for academic CAR‑T development.
KHCC co‑leads the work on validating CAR‑T production, working closely with AUB and under the technical mentorship of Clínic-IDIBAPS. The centre will implement all necessary infrastructure, equipment acquisition, and quality assurance procedures required for CAR‑T manufacturing. Its teams will adapt SOPs, perform environmental testing, and execute three research‑grade CAR‑T production runs, followed by full analytical validation.
In addition to technical implementation, KHCC will contribute to cost assessments and regulatory preparations to ensure the future adoption of ARI-001 within Jordan’s healthcare system. The Jordan Food and Drug Administration has already expressed support for this national strategic priority.
Through MILenARI, KHCC aims to make cutting‑edge immunotherapies more accessible and affordable for Jordanian and regional patients, reducing reliance on costly commercial products and expanding the country’s capacity for innovative cancer care.
Next Med
